23 results on '"Langley, R."'
Search Results
2. LBA62 Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol
3. SO-9 Pathological primary tumour and lymph node regression following neoadjuvant chemotherapy in resectable oesophagogastric cancer: Pooled analysis of 1619 patients from two randomised trials
4. SO-10 The prognostic role of microarchitecture in tumour-positive lymph nodes in oesophageal cancer patients: Results from the UK MRC OE02 trial
5. SO-6 Microarchitectural changes in regional lymph nodes after chemotherapy in oesophageal cancer: Results from the UK MRC OE02 trial
6. SO-9 The relationship between primary tumour-infiltrating immune cells and immune activation status of tumour draining lymph nodes in oesophageal cancer patients – results from the UK MRC OE02 trial
7. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial
8. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report†
9. O-9 Discordant prognostic significance of negative lymph node size in patients with oesophageal cancer treated with either surgery or neoadjuvant chemotherapy and surgery: Results from the MRC OE02 trial
10. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
11. Docetaxel for hormone-naïve prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial
12. Magnetic resonance imaging in oesophageal (oes) cancer: Results from the STO3 MRI substudy
13. ATM loss, MSI and survival in the MAGIC trial
14. 855PD - Docetaxel for hormone-naïve prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial
15. A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948)
16. 637P - Magnetic resonance imaging in oesophageal (oes) cancer: Results from the STO3 MRI substudy
17. LBA-03 Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072)
18. 647P - ATM loss, MSI and survival in the MAGIC trial
19. Are the Benefits of Aspirin in Colorectal Cancer Limited to PIK3CA Mutated Cancers?
20. LBA26 - A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948)
21. O-0012 - Are the Benefits of Aspirin in Colorectal Cancer Limited to PIK3CA Mutated Cancers?
22. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
23. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.